How much funding has Nektar Therapeutics raised?

Nektar Therapeutics has raised $460.0M in total funding, most recently a Corporate Round.

When was Nektar Therapeutics founded?

Nektar Therapeutics was founded in 1990.

Where is Nektar Therapeutics headquartered?

Nektar Therapeutics is headquartered in San Francisco, California, United States.

What industry is Nektar Therapeutics in?

Nektar Therapeutics operates in Biotech, Healthcare, immunotherapy.

How many employees does Nektar Therapeutics have?

Nektar Therapeutics has 51-200 employees.

Nektar Therapeutics

IPO

Pioneering science to transform patient lives through innovative immunology therapies

Public · San Francisco, United States · Founded 1990 · $460.0M raised

Biotech

Healthcare

immunotherapy

Headquarters: San Francisco, California
Employees: 51–200
Founded: 1990
Business Model: B2B
Website: nektar.com

Total Funding: $460.0M
Last Round: $460.0M Corporate RoundFeb 2026
Rounds: 1
Type: Public

About

Nektar Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 1990, Nektar has led development in PEGylation technology — attaching polyethylene glycol (PEG) polymer chains to drug molecules to improve their pharmacokinetics. The company subsequently pivoted to immunology, developing novel small-molecule and biologic therapies for conditions including atopic dermatitis and multiple sclerosis. Its lead asset NKTR-0165 demonstrated strong Phase 2b results in eczema in early 2026. Nektar went public in 1994 (Nasdaq: NKTR).

Summary

Nektar Therapeutics is a Biotech company based in San Francisco, United States, founded in 1990. It has raised $460.0M in total across 1 round, most recently a $460.0M Corporate Round round in Feb 2026.